Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00311105 | Thyroid | PTC | regulation of microtubule polymerization or depolymerization | 44/5968 | 88/18723 | 3.00e-04 | 2.11e-03 | 44 |
GO:006014716 | Thyroid | PTC | regulation of posttranscriptional gene silencing | 29/5968 | 52/18723 | 3.09e-04 | 2.15e-03 | 29 |
GO:005149419 | Thyroid | PTC | negative regulation of cytoskeleton organization | 73/5968 | 163/18723 | 3.59e-04 | 2.44e-03 | 73 |
GO:00109778 | Thyroid | PTC | negative regulation of neuron projection development | 63/5968 | 137/18723 | 3.70e-04 | 2.50e-03 | 63 |
GO:004592614 | Thyroid | PTC | negative regulation of growth | 105/5968 | 249/18723 | 3.76e-04 | 2.54e-03 | 105 |
GO:00435245 | Thyroid | PTC | negative regulation of neuron apoptotic process | 66/5968 | 145/18723 | 3.88e-04 | 2.61e-03 | 66 |
GO:00069709 | Thyroid | PTC | response to osmotic stress | 42/5968 | 84/18723 | 4.07e-04 | 2.73e-03 | 42 |
GO:00311096 | Thyroid | PTC | microtubule polymerization or depolymerization | 57/5968 | 122/18723 | 4.19e-04 | 2.81e-03 | 57 |
GO:19043534 | Thyroid | PTC | regulation of telomere capping | 17/5968 | 26/18723 | 4.57e-04 | 3.01e-03 | 17 |
GO:00609669 | Thyroid | PTC | regulation of gene silencing by RNA | 29/5968 | 53/18723 | 4.76e-04 | 3.13e-03 | 29 |
GO:00613873 | Thyroid | PTC | regulation of extent of cell growth | 52/5968 | 110/18723 | 5.20e-04 | 3.37e-03 | 52 |
GO:006096417 | Thyroid | PTC | regulation of gene silencing by miRNA | 27/5968 | 49/18723 | 6.38e-04 | 4.02e-03 | 27 |
GO:0051972110 | Thyroid | PTC | regulation of telomerase activity | 26/5968 | 47/18723 | 7.38e-04 | 4.59e-03 | 26 |
GO:00989305 | Thyroid | PTC | axonal transport | 33/5968 | 64/18723 | 8.26e-04 | 5.11e-03 | 33 |
GO:003519616 | Thyroid | PTC | production of miRNAs involved in gene silencing by miRNA | 28/5968 | 52/18723 | 8.33e-04 | 5.13e-03 | 28 |
GO:000725419 | Thyroid | PTC | JNK cascade | 73/5968 | 167/18723 | 8.41e-04 | 5.17e-03 | 73 |
GO:0070302110 | Thyroid | PTC | regulation of stress-activated protein kinase signaling cascade | 83/5968 | 195/18723 | 1.04e-03 | 6.21e-03 | 83 |
GO:0051973111 | Thyroid | PTC | positive regulation of telomerase activity | 20/5968 | 34/18723 | 1.07e-03 | 6.32e-03 | 20 |
GO:00303087 | Thyroid | PTC | negative regulation of cell growth | 80/5968 | 188/18723 | 1.28e-03 | 7.31e-03 | 80 |
GO:0032872110 | Thyroid | PTC | regulation of stress-activated MAPK cascade | 81/5968 | 192/18723 | 1.62e-03 | 8.95e-03 | 81 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP2 | SNV | Missense_Mutation | | c.5158G>A | p.Gly1720Ser | p.G1720S | P11137 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP2 | SNV | Missense_Mutation | novel | c.5438N>G | p.Thr1813Ser | p.T1813S | P11137 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP2 | SNV | Missense_Mutation | | c.1633N>C | p.Asp545His | p.D545H | P11137 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.771) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
MAP2 | SNV | Missense_Mutation | rs780652765 | c.4724G>A | p.Arg1575Gln | p.R1575Q | P11137 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A7-A426-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MAP2 | SNV | Missense_Mutation | | c.2813A>G | p.His938Arg | p.H938R | P11137 | protein_coding | tolerated_low_confidence(0.89) | benign(0.038) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP2 | SNV | Missense_Mutation | | c.2342N>T | p.Gln781Leu | p.Q781L | P11137 | protein_coding | deleterious(0) | benign(0.129) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
MAP2 | SNV | Missense_Mutation | novel | c.2427N>T | p.Met809Ile | p.M809I | P11137 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP2 | SNV | Missense_Mutation | novel | c.4259N>T | p.Ser1420Leu | p.S1420L | P11137 | protein_coding | deleterious(0) | benign(0.015) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
MAP2 | SNV | Missense_Mutation | | c.1849N>A | p.Asp617Asn | p.D617N | P11137 | protein_coding | deleterious_low_confidence(0.01) | benign(0.31) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP2 | SNV | Missense_Mutation | novel | c.343N>G | p.Gln115Glu | p.Q115E | P11137 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.977) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |